News | August 17, 2025
AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
NewCo’s pipeline includes five investigational medicines
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
